Claesson Jan-Eric, Kristensson Bo-Erik, Edvardsson Nils, Währborg Peter
School of Life Sciences, University of Skövde, PO Box 408, S-541 28 Skövde, Sweden.
Europace. 2007 Oct;9(10):932-6. doi: 10.1093/europace/eum180. Epub 2007 Sep 5.
The aim of this study was to examine the effect on symptoms in patients with induced cardioinhibitory carotid sinus syndrome (ICSS) when treated or not treated with a pacemaker.
Sixty patients with a history of syncope or pre-syncope and ICSS were randomized to receive a permanent pacemaker (P group, n = 30) or no pacing (NP group, n = 30). ICSS was defined as a ventricular pause (i.e. asystole) lasting 3 s or more in response to carotid sinus stimulation. The patients were seen at 3 and 12 months and at symptoms. At 12 months, the rate of syncope in the NP group was 40% (n = 12) compared with 10% (n = 3) in the P group (P = 0.008). The majority (11 of 12) of the syncope recurrences in the NP group occurred during the first 3 months. Pre-syncope occurred in two patients (7%) in the NP group and in eight (27%) in the P group. Ten patients (33%) with recurrent syncope in the NP group later crossed-over to receive pacemaker implant.
A history of syncope or pre-syncope, plus ICSS, was a strong predictor of subsequent syncope or pre-syncope. Most of the new symptoms occurred within 3 months. Pacemaker treatment effectively reduced syncope and/or resulted in milder symptoms.
本研究旨在探讨起搏器治疗或未治疗对诱发性心脏抑制型颈动脉窦综合征(ICSS)患者症状的影响。
60例有晕厥或先兆晕厥病史且患有ICSS的患者被随机分为接受永久性起搏器治疗组(P组,n = 30)或未进行起搏治疗组(NP组,n = 30)。ICSS定义为对颈动脉窦刺激反应出现持续3秒或更长时间的心室停搏(即心脏停搏)。在3个月、12个月时对患者进行随访并观察症状。12个月时,NP组晕厥发生率为40%(n = 12),而P组为10%(n = 3)(P = 0.008)。NP组大多数(12例中的11例)晕厥复发发生在最初3个月内。NP组有2例患者(7%)出现先兆晕厥,P组有8例(27%)。NP组10例(33%)反复晕厥患者后来交叉接受了起搏器植入。
晕厥或先兆晕厥病史,加上ICSS,是后续晕厥或先兆晕厥的有力预测指标。大多数新症状在3个月内出现。起搏器治疗有效减少了晕厥和/或使症状减轻。